Dr. Jae Wook Hyeon earned his B.S. in molecular and food biotechnology from Gachon University and his Ph.D. in pharmacology from Chungbuk National University. During his graduate research, he worked at the Korea National Institute of Health, Centers for Disease Control and Prevention, as a senior researcher. His graduate studies focused on improvement of diagnostic methods and search for inhibitory compounds for human prion diseases. His expertise lies in protein aggregation assay, cell line (neuronal) and mice (transgenic, knockout) assays, western blotting, ELISA, cloning, molecular works, protein purification (FPLC), microscopic assay, IHC,and ICC. In 2019, he joined the laboratory of Dr. Jiyan Ma at Van Andel Institute as a postdoctoral fellow.
Studying prion protein purification and screening of nanobodies.
Ph.D. in pharmacology, Chungbuk National University (South Korea) (Advisor: Dr. MyungKoo Lee)
Thesis: Improvement of diagnostic methods and search for inhibitory compounds for human prion diseases
B.S. in molecular and food biotechnology, Gachon University (South Korea)
To view a list of selected publications click below.
Lee SM, Hyeon JW, Kim SJ, Kim H, Noh R, Kim S, Lee YS, Kim SY. 2019. Sensitivity and specificity evaluation of multiple neurodegenerative proteins for Creutzfeldt-Jakob disease diagnosis using a deep-learning approach. Prion 13(1):141-150.
Hwang H G, Kim DH, Lee J, Mo Y, Lee SH, Lee Y, Hyeon JW, Lee SM, Cheon YP, Choi EK, Kim SY, Lee YS, Son YJ, Ryou C. 2018. High-level production of high-purity human and murine recombinant prion proteins functionally compatible to in vitro seeding assay. J Microbiol Biotechnol 28(10):1749–1759.
Hyeon JW, Kim SY, Lee SM, Lee J, An SS, Lee MK, Lee YS. 2017. Anti-prion screening for acridine, dextran, and tannic acid using real time-quaking induced conversion: A comparison with PrPSc-infected cell screening. PLoS One 12(1):e0170266.
Choi J, Govindaraj RG, Hyeon JW, Lee K, Ma S, Kim SY, Lee J, No ST. 2017. Structural insight into the antiprion compound inhibition mechanism of native prion folding over misfolding. Chem Biol Drug Des 89(6):907–917.
Lee SM, Chung M, Hyeon JW, Jeong SW, Ju YR, Kim H, Lee J, Kim S, An SS, Cho SB, Lee YS, Kim SY. 2016. Genomic characteristics of genetic Creutzfeldt-Jakob disease patients with V180I mutation and associations with other neurodegenerative disorders. PLoS One 11(6):e0157540.
Hyeon JW, Choi J, Kim SY, Govindaraj RG, Jam Hwang K, Lee YS, An SS, Lee MK, Joung JY, No KT, Lee J. 2015. Discovery of novel anti-prion compounds using in silico and in vitro approaches. Sci Rep 5:14944.
Hyeon JW, Kim SY, Lee J, Park JS, Hwang KJ, Lee SM, An SA, Lee MK, Ju YR. 2015. Alternative application of Tau protein in Creutzfeldt-Jakob disease diagnosis: Improvement for weakly positive 14-3-3 protein in the laboratory. Sci Rep 5:15283.
Lee J, Hyeon JW, Kim SY, Hwang KJ, Ju YR, Ryou C. 2015. Review: Laboratory diagnosis and surveillance of Creutzfeldt-Jakob disease. J Med Virol 87(1):175–186.
Lee SM, Chung M, Hwang KJ, Ju YR, Hyeon KW, Park JS, Kim CK, Choi S, Lee J, Kim SY. 2014. Biological network inferences for a protection mechanism against familial Creutzfeldt-Jakob disease with E200K pathogenic mutation. BMC Med Genomics 7:52.
Hyeon JW, Kim SY, Park JS, Choi BY, Lee SM, Ju YR, An SS, Kim CK. 2012. The association between prion proteins and Abeta(1)(-)(4)(2) oligomers in cytotoxicity and apoptosis. Biochem 424(2):214–220.